Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients
Background and Aim: Immune status profile can predict response to vaccination, while lymphocyte phenotypic alterations represent its effectiveness. We prospectively evaluated these parameters in kidney transplant recipients (KTRs) regarding Tozinameran (BNT162b2) vaccination. Method: In this prospec...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/10/1583 |
| _version_ | 1797572072473362432 |
|---|---|
| author | Stamatia Stai Asimina Fylaktou Efstratios Kasimatis Aliki Xochelli Georgios Lioulios Vasiliki Nikolaidou Anastasia Papadopoulou Grigorios Myserlis Artemis Maria Iosifidou Myrto Aikaterini Iosifidou Aikaterini Papagianni Evangelia Yannaki Georgios Tsoulfas Maria Stangou |
| author_facet | Stamatia Stai Asimina Fylaktou Efstratios Kasimatis Aliki Xochelli Georgios Lioulios Vasiliki Nikolaidou Anastasia Papadopoulou Grigorios Myserlis Artemis Maria Iosifidou Myrto Aikaterini Iosifidou Aikaterini Papagianni Evangelia Yannaki Georgios Tsoulfas Maria Stangou |
| author_sort | Stamatia Stai |
| collection | DOAJ |
| description | Background and Aim: Immune status profile can predict response to vaccination, while lymphocyte phenotypic alterations represent its effectiveness. We prospectively evaluated these parameters in kidney transplant recipients (KTRs) regarding Tozinameran (BNT162b2) vaccination. Method: In this prospective monocenter observational study, 39 adult KTRs, on stable immunosuppression, naïve to COVID-19, with no protective humoral response after two Tozinameran doses, received the third vaccination dose, and, based on their immunity activation, they were classified as responders or non-responders. Humoral and cellular immunities were assessed at predefined time points (T<sub>0</sub>: 48 h before the first, T<sub>1</sub>: 48 h prior to the third and T<sub>2</sub>: three weeks after the third dose). Results: Responders, compared to non-responders, had a higher total and transitional B-lymphocyte count at baseline (96.5 (93) vs. 51 (52)cells/μL, <i>p</i>: 0.045 and 9 (17) vs. 1 (2)cells/μL, <i>p</i>: 0.031, respectively). In the responder group, there was a significant increase, from T<sub>0</sub> to T<sub>1,</sub> in the concentrations of activated CD4+ (from 6.5 (4) to 10.08 (11)cells/μL, <i>p:</i> 0.001) and CD8+ (from 8 (19) to 14.76 (16)cells/μL, <i>p</i>: 0.004) and a drop in CD3+PD1+ T-cells (from 130 (121) to 30.44 (25)cells/μL, <i>p</i>: 0.001), while naïve and transitional B-cells increased from T<sub>1</sub> to T<sub>2</sub> (from 57.55 (66) to 1149.3 (680)cells/μL, <i>p</i> < 0.001 and from 1.4 (3) to 17.5 (21)cells/μL, <i>p</i>: 0.003). The percentages of memory and marginal zone B-lymphocytes, and activated CD4+, CD8+ and natural killer (NK) T-cells significantly increased, while those of naïve B-cells and CD3+PD1+ T-cells reduced from T<sub>0</sub> to T<sub>1</sub>. Conclusions: Responders and non-responders to the third BNT162b2 dose demonstrated distinct initial immune cell profiles and changes in cellular subpopulation composition following vaccination. |
| first_indexed | 2024-03-10T20:49:35Z |
| format | Article |
| id | doaj.art-21a0b511c99c4768910b7a7dd4499840 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T20:49:35Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-21a0b511c99c4768910b7a7dd44998402023-11-19T18:24:55ZengMDPI AGVaccines2076-393X2023-10-011110158310.3390/vaccines11101583Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant RecipientsStamatia Stai0Asimina Fylaktou1Efstratios Kasimatis2Aliki Xochelli3Georgios Lioulios4Vasiliki Nikolaidou5Anastasia Papadopoulou6Grigorios Myserlis7Artemis Maria Iosifidou8Myrto Aikaterini Iosifidou9Aikaterini Papagianni10Evangelia Yannaki11Georgios Tsoulfas12Maria Stangou13School of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceDepartment of Immunology, National Histocompatibility Center, Hippokration General Hospital, 54642 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceDepartment of Immunology, National Histocompatibility Center, Hippokration General Hospital, 54642 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceDepartment of Immunology, National Histocompatibility Center, Hippokration General Hospital, 54642 Thessaloniki, GreeceHematology Department, Hematopoietic Cell Transplantation Unit, Gene and Cell Therapy Center, “George Papanikolaou” Hospital, 57010 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceHematology Department, Hematopoietic Cell Transplantation Unit, Gene and Cell Therapy Center, “George Papanikolaou” Hospital, 57010 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thessaloniki, GreeceBackground and Aim: Immune status profile can predict response to vaccination, while lymphocyte phenotypic alterations represent its effectiveness. We prospectively evaluated these parameters in kidney transplant recipients (KTRs) regarding Tozinameran (BNT162b2) vaccination. Method: In this prospective monocenter observational study, 39 adult KTRs, on stable immunosuppression, naïve to COVID-19, with no protective humoral response after two Tozinameran doses, received the third vaccination dose, and, based on their immunity activation, they were classified as responders or non-responders. Humoral and cellular immunities were assessed at predefined time points (T<sub>0</sub>: 48 h before the first, T<sub>1</sub>: 48 h prior to the third and T<sub>2</sub>: three weeks after the third dose). Results: Responders, compared to non-responders, had a higher total and transitional B-lymphocyte count at baseline (96.5 (93) vs. 51 (52)cells/μL, <i>p</i>: 0.045 and 9 (17) vs. 1 (2)cells/μL, <i>p</i>: 0.031, respectively). In the responder group, there was a significant increase, from T<sub>0</sub> to T<sub>1,</sub> in the concentrations of activated CD4+ (from 6.5 (4) to 10.08 (11)cells/μL, <i>p:</i> 0.001) and CD8+ (from 8 (19) to 14.76 (16)cells/μL, <i>p</i>: 0.004) and a drop in CD3+PD1+ T-cells (from 130 (121) to 30.44 (25)cells/μL, <i>p</i>: 0.001), while naïve and transitional B-cells increased from T<sub>1</sub> to T<sub>2</sub> (from 57.55 (66) to 1149.3 (680)cells/μL, <i>p</i> < 0.001 and from 1.4 (3) to 17.5 (21)cells/μL, <i>p</i>: 0.003). The percentages of memory and marginal zone B-lymphocytes, and activated CD4+, CD8+ and natural killer (NK) T-cells significantly increased, while those of naïve B-cells and CD3+PD1+ T-cells reduced from T<sub>0</sub> to T<sub>1</sub>. Conclusions: Responders and non-responders to the third BNT162b2 dose demonstrated distinct initial immune cell profiles and changes in cellular subpopulation composition following vaccination.https://www.mdpi.com/2076-393X/11/10/1583kidney transplantationCOVID-19 vaccinationlymphocytesprotective humoral responsecellular responseELISpot |
| spellingShingle | Stamatia Stai Asimina Fylaktou Efstratios Kasimatis Aliki Xochelli Georgios Lioulios Vasiliki Nikolaidou Anastasia Papadopoulou Grigorios Myserlis Artemis Maria Iosifidou Myrto Aikaterini Iosifidou Aikaterini Papagianni Evangelia Yannaki Georgios Tsoulfas Maria Stangou Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients Vaccines kidney transplantation COVID-19 vaccination lymphocytes protective humoral response cellular response ELISpot |
| title | Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients |
| title_full | Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients |
| title_fullStr | Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients |
| title_full_unstemmed | Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients |
| title_short | Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients |
| title_sort | immune profile determines response to vaccination against covid 19 in kidney transplant recipients |
| topic | kidney transplantation COVID-19 vaccination lymphocytes protective humoral response cellular response ELISpot |
| url | https://www.mdpi.com/2076-393X/11/10/1583 |
| work_keys_str_mv | AT stamatiastai immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT asiminafylaktou immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT efstratioskasimatis immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT alikixochelli immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT georgioslioulios immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT vasilikinikolaidou immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT anastasiapapadopoulou immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT grigoriosmyserlis immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT artemismariaiosifidou immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT myrtoaikateriniiosifidou immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT aikaterinipapagianni immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT evangeliayannaki immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT georgiostsoulfas immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients AT mariastangou immuneprofiledeterminesresponsetovaccinationagainstcovid19inkidneytransplantrecipients |